Rapid Micro Biosystems, Inc.

NasdaqGS:RPID Stock Report

Market Cap: US$42.1m

Rapid Micro Biosystems Past Earnings Performance

Past criteria checks 0/6

Rapid Micro Biosystems's earnings have been declining at an average annual rate of -6.3%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 1% per year.

Key information

-6.3%

Earnings growth rate

98.8%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate1.0%
Return on equity-44.5%
Net Margin-233.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Oct 10

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

May 09
Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Mar 08
Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Feb 07
We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Revenue & Expenses Breakdown
Beta

How Rapid Micro Biosystems makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:RPID Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2323-523813
30 Sep 2321-584113
30 Jun 2319-614213
31 Mar 2318-604212
31 Dec 2217-614213
30 Sep 2218-594012
30 Jun 2220-683712
31 Mar 2222-693411
31 Dec 2123-783010
30 Sep 2123-77269
30 Jun 2122-63218
31 Mar 2118-60187
31 Dec 2016-45167
31 Dec 1917-27135

Quality Earnings: RPID is currently unprofitable.

Growing Profit Margin: RPID is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RPID is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.

Accelerating Growth: Unable to compare RPID's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RPID is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).


Return on Equity

High ROE: RPID has a negative Return on Equity (-44.47%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.